An Australia Patent on ITE for Cancer Intervention and Eradication Issued to AhR Pharmaceuticals, IncAhR Pharmaceuticals Announces the Issuance of an Australia Patent by the IP Australia
ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor (AhR). Once bound to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community as well have demonstrated ITE's potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems. "We are devoted to the development of a unique treatment and possible cure for cancer patients and this is the recognition by IP Australia of our efforts in innovation and invention in the area," said Dr. Jiasheng (Jason) Song, the Chief Scientific Officer of AhR Pharmaceuticals. "We will continue the efforts in innovation and protection of our important inventions," The patent (2010313622) AhR Pharmaceuticals, Inc., with licensed ITE technologies as its foundational intellectual property from Wisconsin Alumni Research Foundation (WARF, the intellectual property manager of University of Wisconsin-Madison, a world-renowned research university), is devoted to the development of the natural hormone ITE and its structural analogs into an efficacious and sustainable but low side-effect therapeutic agent in intervention and possible eradication of cancer, obesity, and disorders due to imbalanced actions of immune systems. For more information on AhR Pharmaceuticals, Inc., its technologies, and research activities, please visit www.ahrpharma.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|